Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medexus PharmaceuticalsTSX:MDP +1.32%53 Equity-to-Asset is 0.34 as of Jun. 2026, which is 55% above its 10-year median of 0.22. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$2.04 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Medexus Pharmaceuticals ranks worse than 80.62% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medexus Pharmaceuticals Equity-to-Asset Related Terms
Medexus Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medexus Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medexus Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medexus Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medexus Pharmaceuticals (TSX:MDP) has a Equity-to-Asset of 0.34 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medexus Pharmaceuticals and its competitors. This is 55% above median its historical median of 0.22. According to the industry distribution chart, Medexus Pharmaceuticals ranks #811 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 80.6%.
Is Medexus Pharmaceuticals' Equity-to-Asset too high?
Medexus Pharmaceuticals' current Equity-to-Asset of 0.34 is 55% above median its 10-year median of 0.22. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Medexus Pharmaceuticals' value of 0.34 is 44.3% below this industry median. Based on the distribution chart, Medexus Pharmaceuticals ranks #811 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medexus Pharmaceuticals ranks #811 out of 1006 companies for Equity-to-Asset. This places Medexus Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Medexus Pharmaceuticals' value of 0.34 is 44.3% below this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 0.61, Medexus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medexus Pharmaceuticals's current Equity-to-Asset of 0.34 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medexus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medexus Pharmaceuticals's current Equity-to-Asset is 0.34, which is 55% above median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$2.04, compared to a current price of C$5.37 — trading 163.2% above its estimated fair value. The current Equity-to-Asset is 0.34, which is 55% above median its 10-year median of 0.22 and 44.3% below the Drug Manufacturers industry median of 0.61. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Equity-to-Asset is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued.
The current stock price of C$5.37 is trading 163.2% above its estimated GF Value™ of C$2.04.
GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSX:MDP:
Equity-to-Asset: 0.34 (55% above median its 10-year median of 0.22)
GF Value™: C$2.04 vs. price of C$5.37 (163.2% above fair value)
Industry Position: 44.3% below the Drug Manufacturers median (#811 of 1006)
No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score
Get the complete analysis for TSX:MDP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MDP has been successfully added to your 
